Skip to content

Epimorph COVID Acute Respiratory Distress Syndrome

Epidural Morphine in COVID ARDS patients with abnormally high respiratory drive: a double-blind, randomized controlled trial - EpimorphCARDS

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/07/035093
Enrollment
50
Registered
2021-07-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Epidural Morphine: Patients with High Respiratory Drive ( TFDi 30%) will be administered Epidural morphine 5 mg -10 mg in escalating doses once every 18-24 hours Control Intervention1:

Sponsors

Swagata Tripathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: COVID 19 ARDS patients on NIV, P/F Ration 30% ( secondary - Vt > 10 ml/ kg. RR > 25 /min )

Exclusion criteria

Exclusion criteria: Metabolic acidosis HCO3- < 16 or pH < 7.2. Severe hypoxemia warranting cessation of NIV and intubation, non-acceptance of NIV. Technical difficulty for epidural catheterization, coagulation abnormalities, low respiratory drive, EOL orders, chronic opioid use.

Design outcomes

Primary

MeasureTime frame
Diaphragm thickening index fractionTimepoint: Average of 3 readings at 3 time points each 24 hours, for the duration of minimum 48 hours and a maximum of 100 hours

Secondary

MeasureTime frame
Ventilatory parameters, sedation and pain scores, subjective comfort and dyspnoea scores, time to intubation, length of stay on NIV, 28 day mortality.Timepoint: Average of 3 readings at 3 time points each 24 hours, for the duration of minimum 48 hours and a maximum of 100 hours

Countries

India

Contacts

Public Contactswagata Tripathy

AII India Institute of Medical Sciences

tripathyswagata@gmail.com918763400534

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 21, 2026